Novel inhibitors of the (VIBVN) NAT protein identified through pharmacophore modeling
Abstract Arylamine N-acetyltransferases (NATs, E.C. 2.3.1.5) constitute a family of phase II drug metabolizing enzymes. These enzymes catalyze the transfer of acetyl groups from acetyl-CoA to a variety of substrates including arylamines, arylhydrazines, and N-hydroxyarylamines. By facilitating these...
Saved in:
Main Authors: | Wei Wei, Xionghao Li, Ning Hou, Aowei Xie, Huicong Liang, Ting Gao, Xiaoli Jing, Liqin Li, Jiejie Hao, Ximing Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-025-85869-4 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ligand-Based Pharmacophore Modeling and Virtual Screening of RAD9 Inhibitors
by: Nirmal K. Prasad, et al.
Published: (2013-01-01) -
Identification of New Potential APE1 Inhibitors by Pharmacophore Modeling and Molecular Docking
by: In Won Lee, et al.
Published: (2017-12-01) -
EGFR inhibition augments the therapeutic efficacy of the NAT10 inhibitor Remodelin in Colorectal cancer
by: Yongbin Zheng, et al.
Published: (2025-02-01) -
Identification of Novel LCN2 Inhibitors Based on Construction of Pharmacophore Models and Screening of Marine Compound Libraries by Fragment Design
by: Ningying Zheng, et al.
Published: (2025-01-01) -
dyphAI dynamic pharmacophore modeling with AI: a tool for efficient screening of new acetylcholinesterase inhibitors
by: Yasser Hayek-Orduz, et al.
Published: (2025-02-01)